Repositorio Dspace

Elexacaftor/tezacaftor/ivacaftor for cystic fibrosis and rare CFTR variants: in vitro translation to a phase 3, double-blind, randomized, placebo-controlled trial, and real-world study

Mostrar el registro sencillo del ítem

dc.contributor.author Castellani, Carlo
dc.contributor.author Mondéjar-López, Pedro
dc.contributor.author Van-Goor, Fredrick
dc.contributor.author Quon, Bradley-S
dc.contributor.author Alghisi, Federico
dc.contributor.author Fabrizzi, Benedetta
dc.contributor.author Ramsey, Bonnie
dc.contributor.author Taylor-Cousar, Jennifer-L
dc.contributor.author McKone, Edward-F
dc.contributor.author Tullis, Elizabeth
dc.contributor.author Weinstock, Tanya-G
dc.contributor.author Tan, Vincent
dc.contributor.author Ahluwalia, Neil
dc.contributor.author Mahic, Milada
dc.contributor.author Liu, Lingyun
dc.contributor.author Saayman, Sheena
dc.contributor.author Altshuler, David
dc.contributor.author Waltz, David
dc.contributor.author Mall, Marcus-A
dc.contributor.author Fajac, Isabelle
dc.date.accessioned 2026-09-17T12:11:25Z
dc.date.available 2026-09-17T12:11:25Z
dc.date.issued 2026-02-01
dc.identifier.issn 1073-449X
dc.identifier.uri https://sms.carm.es/ricsmur/handle/123456789/28029
dc.description.abstract RATIONALE: Elexacaftor/tezacaftor/ivacaftor, a CF transmembrane conductance regulator (CFTR) modulator, stabilizes and restores F508del-CFTR function, which is the most common CFTR variant. In multiple clinical and real-world studies, elexacaftor/tezacaftor/ivacaftor was shown to be safe and highly effective in people with CF carrying at least one F508del-CFTR (?80% of people with CF). OBJECTIVES: To characterize the response of rare, non-F508del CFTR variants to elexacaftor/tezacaftor/ivacaftor in vitro, and in clinical and real-world studies. METHODS: We engineered Fischer rat thyroid (FRT) cells each of which express 1 of 620 rare exonic CFTR variants present in public databases and evaluated their in vitro response to elexacaftor/tezacaftor/ivacaftor. We evaluated efficacy and safety of elexacaftor/tezacaftor/ivacaftor in a 24-week randomized, placebo-controlled, Phase 3 trial (445-124) in participants with 1 of 18 rare variants and no F508del and in a real-world study (CFD-016) in people carrying 82 rare variants and no F508del. MEASUREMENTS AND MAIN RESULTS: In FRT cells, 518 of 620 (84%) rare variants responded to elexacaftor/tezacaftor/ivacaftor. In 445-124, mean improvements were seen in the primary endpoint of percent predicted FEV1 (9.2 percentage points [95% CI: 7.2, 11.3; P < .0001]), and secondary endpoints of sweat chloride (-28.3 mmol/L [95% CI: -32.1, -24.5 mmol/L; P < .0001]) and CFQ-R RD (19.5 points [95% CI: 15.5, 23.5; P < .0001]). In CFD-016, improvements in lung function were seen after treatment initiation. CONCLUSIONS: In vitro, clinical, and real-world data support elexacaftor/tezacaftor/ivacaftor treatment in people carrying a range of CFTR variants and no F508del. The response of 84% of rare CFTR variants that produce protein to protein-stabilizing therapy suggests variants in many regions of the protein causes disease via protein destabilization.
dc.language.iso eng
dc.publisher OXFORD UNIV PRESS
dc.rights Atribución/Reconocimiento-NoComercial 4.0 Internacional 
dc.rights.uri https://creativecommons.org/licenses/by-nc/4.0/deed.es  *
dc.subject.mesh Cystic Fibrosis/drug therapy/genetics
dc.subject.mesh Humans
dc.subject.mesh Cystic Fibrosis Transmembrane Conductance Regulator/genetics/drug effects
dc.subject.mesh Indoles/therapeutic use
dc.subject.mesh Animals
dc.subject.mesh Quinolones/therapeutic use
dc.subject.mesh Double-Blind Method
dc.subject.mesh Aminophenols/therapeutic use
dc.subject.mesh Female
dc.subject.mesh Rats
dc.subject.mesh Male
dc.subject.mesh Benzodioxoles/therapeutic use
dc.subject.mesh Pyridines/therapeutic use
dc.subject.mesh Adult
dc.subject.mesh Pyrazoles/therapeutic use
dc.subject.mesh Drug Combinations
dc.subject.mesh Pyrrolidines/therapeutic use
dc.subject.mesh Rats, Inbred F344
dc.subject.mesh Adolescent
dc.subject.mesh Quinuclidines/therapeutic use
dc.subject.mesh Young Adult
dc.subject.mesh Pyrroles/therapeutic use
dc.subject.mesh Quinolines
dc.title Elexacaftor/tezacaftor/ivacaftor for cystic fibrosis and rare CFTR variants: in vitro translation to a phase 3, double-blind, randomized, placebo-controlled trial, and real-world study
dc.type info:eu-repo/semantics/article 
dc.identifier.pmid 41738096
dc.relation.publisherversion https://academic.oup.com/ajrccm/article/212/2/327/8435645
dc.type.version info:eu-repo/semantics/publishedVersion 
dc.identifier.doi 10.1093/ajrccm/aamaf001
dc.journal.title AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
dc.identifier.essn 1535-4970


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución/Reconocimiento-NoComercial 4.0 Internacional  Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución/Reconocimiento-NoComercial 4.0 Internacional 

Buscar en DSpace


Búsqueda avanzada

Listar

Mi cuenta